Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Small cell lung cancer (SCLC) has long been a master of disguise — evading the immune system and resisting the immunotherapy breakthroughs that have transformed other cancers. Researchers at WEHI found that gamma delta T cells can detect and kill SCLC even when the cancer evades conventional immune cells. Better yet, two already-approved drugs can supercharge these cells, potentially opening a new treatment frontier for a disease with a grim survival rate.
Small cell lung cancer (SCLC) has long been a master of disguise — hiding from the immune system and resisting the immunotherapy breakthroughs that have transformed other cancers. Now, researchers at Australia's WEHI institute may have found a way to see through that disguise. Published in Cancer Cell, the study identifies gamma delta T cells as a previously overlooked immune player capable of recognizing and killing SCLC cells, even when the cancer has evaded conventional immune defenses.
The team used miniature lab-grown tumors built from patient samples to show that gamma delta T cells could effectively attack SCLC. They also found that two existing approved drugs — tarlatamab (already used in SCLC) and zoledronate (used for bone disease) — could significantly amplify this immune response, bringing cells closer to tumors and boosting their cancer-killing power.
By the Numbers:
Why it matters: This discovery offers a potential new immunotherapy strategy for one of oncology's toughest challenges — and because it leverages existing approved drugs, clinical translation could move faster than starting from scratch.
